Tue, Oct 21, 2014, 1:33 PM EDT - U.S. Markets close in 2 hrs 27 mins

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

robert.vince 48 posts  |  Last Activity: 5 hours ago Member since: Aug 30, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Clinical Trial for Hep C link

    by toofadedtobeblue 21 hours ago
    robert.vince robert.vince 5 hours ago Flag

    It means that more data should be coming our way by end of July 2015 re hep C

  • Reply to

    AEMD ON CNN (VIDEO)

    by andy55q 16 hours ago
    robert.vince robert.vince 5 hours ago Flag

    No news yet. But when asked how AEMD got involved with the patient in Germany, Joyce said, 'They came to us" and mentioned that they were fully aware of their product.
    I think that's pretty significant as opposed to aemd begging them to try it.

  • Reply to

    AEMD ON CNN (VIDEO)

    by andy55q 16 hours ago
    robert.vince robert.vince 5 hours ago Flag

    they might not have mentioned the company, but they showed its filter which clearly showed the company name and website and contact info. It surely can't hurt, especially if people have a pause button on the remote for when the filter showed up. Filter appears at 1:45 into the video

  • Reply to

    trading halt?

    by onecrazytraderah Oct 17, 2014 10:23 AM
    robert.vince robert.vince Oct 17, 2014 1:17 PM Flag

    The halt if for the entire otc market, not aemd

  • Reply to

    everybody is selling

    by doncikas05 Oct 17, 2014 1:12 PM
    robert.vince robert.vince Oct 17, 2014 1:15 PM Flag

    Its not even down 2 percent, don't think everybody is selling

  • Reply to

    trading halt?

    by onecrazytraderah Oct 17, 2014 10:23 AM
    robert.vince robert.vince Oct 17, 2014 11:42 AM Flag

    There is no halt listed on the otcbb site

  • Yahoo finance won't let me post the link, but a Frankfurt newspaper originally wrote a story about the patient when he was admitted on October 3rd. He was very sick at the time. How sick? Here are a couple of statements from other articles about the patient:

    'On Thursday, the organizers of the flight had long feared, if the patient’s condition would permit even a transport to Germany.' From another article: 'Germany is prepared to treat its second Ebola patient, a hospital in Frankfurt has confirmed. Due to severe symptoms, however, it remained unclear when the patient would arrive.'

    The patient was admitted on October 3rd....
    Here is a statement from the article that I believe is blockbuster:

    'The man's health is "very serious but stable", said Timo Wolf, head of the infectious disease centre at Frankfurt University Hospital.
    The next three days will be decisive, he added, saying the treatment would last "two to three weeks".'

    Well it seems like we FLEW by the 'decisive' point which was on October 6th or so. Folks, its the 17th of October and this too sick to even fly guy is still kicking!

    Its time for Aethlon to Save the World!
    To the moon Alice.....

    Sentiment: Strong Buy

  • robert.vince robert.vince Oct 14, 2014 7:47 AM Flag

    Looks like Aethlon beat us to it:
    Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.

  • Reply to

    Ebola Announcement

    by robert.vince Oct 14, 2014 7:41 AM
    robert.vince robert.vince Oct 14, 2014 7:42 AM Flag

    To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India. In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).

  • Reply to

    Ebola Announcement

    by robert.vince Oct 14, 2014 7:41 AM
    robert.vince robert.vince Oct 14, 2014 7:41 AM Flag

    To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India. In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).

  • robert.vince by robert.vince Oct 14, 2014 7:41 AM Flag

    Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.
    The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. The largest ebola virus epidemic in history is now spreading on a global basis with more than 4,000 deaths being reported by the WHO.
    "We thank the physicians in Frankfurt for allowing us the opportunity to treat this advanced-stage patient," stated Aethlon founder and CEO, Jim Joyce. "Details related to the patient's response to therapy will be disclosed once hospital officials deem it appropriate to report an update on the condition of this individual."
    In the care of ebola-infected individuals, the Hemopurifier targets two unmet medical needs: the rapid elimination of circulating ebola to inhibit continued progeny virus replication and the direct targeting of shed glycoproteins that overwhelm the host immune response. The device can be deployed for use within the global infrastructure of dialysis and CRRT machines already located in hospitals and clinics.
    Aethlon further disclosed that it is preparing to initiate U.S. clinical studies of Hemopurifier therapy based on the United States Food and Drug Administration's (FDA) approval of an Investigational Device Exemption (IDE) that was previously submitted by the Company. The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

  • Reply to

    TT034 HCV Trial Update

    by robert.vince Oct 10, 2014 7:27 AM
    robert.vince robert.vince Oct 10, 2014 7:27 AM Flag

    Dr Peter French, Managing Director and CEO commented, "Appointing Georgina to the position of Senior Drug Development Director is an important step for Benitec. She will work with the company and our clinical investigators to accelerate patient recruitment across all sites, and to ensure the trial progresses as rapidly as the guidelines allow."
    As any other material events occur relating to the trial, Benitec will provide updates to the market. Investors interested in tracking the progress of Benitec's TT-­‐034 trial should monitor progress via announcements lodged through the ASX.

  • robert.vince by robert.vince Oct 10, 2014 7:27 AM Flag

    HCV TRIAL UPDATE Sydney Australia, 8 October 2014: RNAi therapeutics company Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) provides an update regarding progress on the Company's US-­‐based, Phase I/IIa clinical trial for TT-­‐034, a ddRNAi-­‐based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single injection.
    Benitec is pleased to report that the first patient dosed with TT-­‐034, continues to be monitored as per the protocol and that laboratory data indicate that the drug is well tolerated and safe at the dose administered. A second patient has been identified for dosing, and provided the patient continues to stay within the clinical parameters required by the trial protocol during the 28 day screening process, will be dosed as soon as possible following the completion of screening.
    The Company now has two trial sites on line, both of which are actively recruiting
    patients - Duke Clinical Research Centre and University of California San Diego.
    Since the last update, the Company has appointed US-­‐based Senior Drug Development Director, Georgina Kilfoil, with over 22 years in managing clinical trials and in clinical development to take responsibility for three main areas of activity aimed at increasing the rate of recruitment in the TT-­‐034 HCV trial. They are:
    • To liaise with the current trial sites to grow existing clinical trial site recruitment;
    • To advance negotiations with an additional five clinical trial sites in the US, and
    • Appoint specialized patient recruitment vendors across all trial sites

  • Reply to

    Ebola vaccine trials using KLH

    by a_sky_pilot Oct 7, 2014 9:13 PM
    robert.vince robert.vince Oct 8, 2014 9:01 AM Flag

    I see a .php and I'm thinking virus or malware for sure, so I tested the site first, it was safe, went to it, its legit.
    Nice find. BTW, how'd you get to post a link? Anytime I try it, it won't post my topic.

  • Reply to

    Stop it !!

    by sportacus95 Oct 7, 2014 10:45 AM
    robert.vince robert.vince Oct 7, 2014 2:01 PM Flag

    Ok, the company just announced it went bankrupt.... wheeeeee.... watch the share price soar now.
    (just kidding for those of you without a sarcastic sense of humor)

  • Reply to

    Dilution

    by chessen29 Sep 23, 2014 4:16 PM
    robert.vince robert.vince Oct 7, 2014 1:58 PM Flag

    Post the dilution link chessen, i like to be aware of good and bad, but as I'm sure you are well aware of, dilution occurs with even the best startup companies, its a way to keep them alive until they hit paydirt.
    And you can avoid the germs in the paydirt if you put on a vivagel condom now!

  • Durata Therapeutics (DRTX) today announced that the Company has received a Special Protocol Agreement (SPA) from the Food and Drug Administration (FDA) on the design of its Phase 3 study of DALVANCE (dalbavancin) for injection using a 1500 mg single dose for the treatment of patients with community-acquired pneumonia requiring intravenous therapy.

    The study is designed to compare a 1500 mg single IV dose of dalbavancin with linezolid; patients randomized to linezolid can switch to oral therapy after an initial period of IV treatment. All patients will also receive a single IV dose of azithromycin.

    "The Special Protocol Agreement ensures alignment of the trial objectives with the FDA and helps to delineate the path to registration," said Michael Dunne, MD, Durata's Chief Medical Officer. "If successful, DALVANCE would provide a single-dose treatment alternative for patients with community acquired pneumonia effective against the most common bacterial respiratory pathogens, including those resistant to other classes of antibiotics."

    "Durata remains committed to the continued development of DALVANCE in other indications," said Paul R. Edick, Durata's Chief Executive Officer. "In addition to pneumonia and the 1500 mg single dose study in ABSSSI, which is already underway, we look to begin our Phase 3 pediatric osteomyelitis study next year. Important bone penetration data in support of our osteomyelitis development program will be presented in an abstract at IDWeek on Thursday, October 9th."

  • Reply to

    http://www.cytosorb-registry.org/

    by tjastley27 Oct 2, 2014 7:26 AM
    robert.vince robert.vince Oct 2, 2014 9:52 AM Flag

    From the registry:
    Cytosorb has the most benefits for a critical sickest patients with severe SIRS, ie that has that no longer respond to standard therapy. The use should be carried out at an early stage of the disease. The aim is to stabilize the patient at an early stage to perform a turn in the course of the disease induced. The Adsorber with CytoSorb must qualify as very user-friendly. A lasting effect of the treatment was the rapid reduction of catecholamines without rebound effect. The patients could be weaned from the ventilator earlier than expected. "
    Professor Karl carrier head of the cardiac intensive care unit of the University Hospital Ulm

    For large cardiac surgery, it is of course good to have a tool that can catch the mediators, as we find here. Especially in patients with high to infections and Inflammationsparametern the CytoSorb therapy is the right thing. We set the adsorber at a expected long operation times and patients with re-operations and longer machine time at the HLM. I see the CytoSorb therapy in the years established itself as the standard in cardiac surgery in re-operations. In addition, I can imagine that CytoSorb is used in patients with cardiogenic shock or resuscitation among which are then connected to a portable HLM, integrated. "
    Frank Born, M.CT. Cardiac LMU Munich

    Prof. Klaus Krenn, assumes that renal failure without hemodialysis can probably be prevented by the use of CytoSorb therapy in the context of severe sepsis by specifically the increased myoglobin filters out what ultimately the renal tubules can no longer harm. For him it is better to prevent a developing kidney failure, than to cure it later. The CytoSorb therapy is safe and easy to handle. "

    Professor Claus Krenn University of Medicine Vienna

  • Melbourne, Australia; Starpharma today announced the inclusion of the VivaGel® condom in the Australian Register of Therapeutic Goods (ARTG), the final step ahead of market launch in Australia.
    Starpharma’s partner in innovating and bringing this product to market, Ansell (ASX:ANN), has made the necessary preparations, including manufacture of launch supplies, and will launch the VivaGel® condom under the LifeStyles Dual Protect name in Australian retail outlets, including Woolworths stores around the country, during October.
    The VivaGel condom is a world-first product based on innovative Australian technology. It is the only condom of its type, providing barrier protection and also incorporating an antiviral compound (VivaGel) in the lubricant. Australian consumers will be the first globally to access this innovative product discovered and developed in Australia.
    LifeStyles Dual Protect condoms will carry the VivaGel brand and Starpharma will receive royalties based on sales.

  • robert.vince robert.vince Sep 24, 2014 11:38 AM Flag

    The Advisory Board includes: Nima Behkami, PhD, Director of Strategic Alliance, Merck & Co; Paul Murphy, Partner, Betaworks; Ziv Navoth, CEO/Co-Founder, Paragraph; Tarek Pertew, Co-Founder, Wakefield; and Bob Schukai, Head of Advanced Product Innovation at Thomson Reuters.

ALNY
88.56+0.57(+0.65%)1:33 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.